Newsletter | 01 February 2002 Access News 6, Focus on Malaria, February 2002 HIV/AIDS INTELLECTUAL PROPERTY AND TRADE MALARIA TROPICAL & NEGLECTED DISEASES VACCINES How much for an effective malaria treatment is the focus of this edition, as well as MSF in Burundi, Doha and a potential breakthrough, trapped in the ACCESS crisis, life with chagas and HIV and meningitis outbreaks. Read, watch, share Filter by - Any -BlogEventsFeature storyInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefVideo Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations Research article | 14 August 2024 HIV/AIDS Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide Newsletter Newsletter | 02 August 2024 HIV/AIDS Why we went to the International AIDS Conference this year...and what we did! Load More
Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF
Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min
Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access
Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min
Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit
Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations
Research article | 14 August 2024 HIV/AIDS Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide
Newsletter Newsletter | 02 August 2024 HIV/AIDS Why we went to the International AIDS Conference this year...and what we did!
